Trials / Sponsors / IDEAYA Biosciences
IDEAYA Biosciences
Industry · 9 registered clinical trials — 6 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma | Phase 1 | 2026-03-04 |
| Recruiting | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | 2026-02-24 |
| Recruiting | Neoadjuvant Darovasertib in Primary Uveal Melanoma Uveal Melanoma | Phase 3 | 2026-01-25 |
| Recruiting | A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3 | Phase 1 / Phase 2 | 2025-10-14 |
| Active Not Recruiting | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Metastatic Uveal Melanoma | Phase 2 / Phase 3 | 2023-10-31 |
| Active Not Recruiting | (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma Uveal Melanoma | Phase 2 | 2023-07-03 |
| Recruiting | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer | Phase 1 | 2023-04-18 |
| Active Not Recruiting | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion Solid Tumor | Phase 1 | 2021-04-14 |
| Recruiting | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer | Phase 1 / Phase 2 | 2019-06-28 |